文献速递细菌感染、耐药与抗菌药物

在体外、生物膜内和体内测试针对多重耐药肺炎克雷伯菌的吗啉代寡聚体

Morpholino oligomers tested in vitro, in biofilm and in vivo against multidrug-resistant Klebsiella pneumoniae.
PubMed 文献 · J Antimicrob Chemother · 2018-01-01

研究设计肽缀合磷二酰胺吗啉代寡聚体(PPMO)靶向肺炎克雷伯菌必需基因,体外筛选出靶向acpP、rpmB和ftsZ的高效PPMO,其中AcpP PPMO在生物膜中具有杀菌作用。在小鼠肺炎模型中,鼻内治疗性给予约30 mg/kg AcpP PPMO使生存率提高89%,肺部细菌负荷降低约3个对数级,且生存率与剂量成比例。

要点

  • 靶向acpP、rpmB和ftsZ的PPMO MIC75分别为0.5、4和4 μM。
  • AcpP PPMO在1-2倍MIC下具有杀菌作用,并能减少已建立生物膜中的活细胞和生物膜量。
  • 小鼠肺炎模型中,约30 mg/kg AcpP PPMO鼻内治疗使生存率提高89%,肺部细菌负荷降低约3个对数级。

核心结论

  • PPMO有潜力成为针对产KPC多重耐药肺炎克雷伯菌的有效治疗药物。

研究设计与样本

  • 设计靶向肺炎克雷伯菌多种必需基因的PPMO,体外针对一组不同菌株进行筛选。
  • 对最有效的PPMO在肉汤培养和已建立生物膜中进一步测试杀菌效果。
  • 使用PPMO治疗感染产KPC菌株的小鼠。

主要发现

  • 最有效的PPMO靶向acpP、rpmB和ftsZ,MIC75分别为0.5、4和4 μM。
  • AcpP PPMO在1-2倍MIC下具有杀菌作用,并减少已建立生物膜中的活细胞和生物膜量。
  • 小鼠肺炎模型中,治疗性鼻内给予约30 mg/kg AcpP PPMO使生存率提高89%,肺部细菌负荷降低约3个对数级。
  • 生存率与AcpP PPMO剂量成比例。
  • 感染后延迟2、8或24小时治疗,与PBS或乱序序列(Scr)PPMO对照组相比生存率改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Klebsiella pneumoniae is an opportunistic pathogen and many strains are multidrug resistant. KPC is one of the most problematic resistance mechanisms, as it confers resistance to most β-lactams, including carbapenems. A promising platform technology for treating infections caused by MDR pathogens is the nucleic acid-like synthetic oligomers that silence bacterial gene expression by an antisense mechanism. OBJECTIVES: To test a peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) in a mouse model of K. pneumoniae infection. METHODS: PPMOs were designed to target various essential genes of K. pneumoniae and screened in vitro against a panel of diverse strains. The most potent PPMOs were further tested for their bactericidal effects in broth cultures and in established biofilms. Finally, a PPMO was used to treat mice infected with a KPC-expressing strain. RESULTS: The most potent PPMOs targeted acpP, rpmB and ftsZ and had MIC75s of 0.5, 4 and 4 μM, respectively. AcpP PPMOs were bactericidal at 1-2 × MIC and reduced viable cells and biofilm mass in established biofilms. In a mouse pneumonia model, therapeutic intranasal treatment with ∼30 mg/kg AcpP PPMO improved survival by 89% and reduced bacterial burden in the lung by ∼3 logs. Survival was proportional to the dose of AcpP PPMO. Delaying treatment by 2, 8 or 24 h post-infection improved survival compared with control groups treated with PBS or scrambled sequence (Scr) PPMOs. CONCLUSIONS: PPMOs have the potential to be effective therapeutic agents against KPC-expressing, MDR K. pneumoniae.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Geller BL, Li L, Martinez F, et al. Morpholino oligomers tested in vitro, in biofilm and in vivo against multidrug-resistant Klebsiella pneumoniae. J Antimicrob Chemother. 2018. PMID: 29506074. doi:10.1093/jac/dky058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。